PERSPECTA

News from every angle

← Back to headlines

Janux Halts Development of Tumor-Activated T Cell Engager Drug

Biopharmaceutical company Janux Therapeutics has announced the discontinuation of its Tumor Activated T Cell Engager asset, impacting its drug development pipeline.

27 Apr, 20:36 — 27 Apr, 20:36
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed5h ago

Janux ends development of Tumor Activated T Cell Engager asset

Read full article →

Related Stories

Menopause: The Natural Stage of Significant Bodily Changes

15m ago

Nigerian Government Intensifies Tsetse Fly Control in Multiple States

22m ago

Woman Gives Birth Mid-Flight on Delta From Atlanta to Portland

46m ago

Experts Call for Improved Funding and Staffing in Ogun State Health Sector

51m ago